Session » Miscellaneous Rheumatic & Inflammatory Diseases Poster III

Date: Monday, November 18, 2024

Time: 10:30AM-12:30PM

Meeting: ACR Convergence 2024

10:30AM-12:30PM: Abstract Number: 2031

A Contemporary Assessment of the Burden of Malignancy in IgG4-Related Disease

10:30AM-12:30PM: Abstract Number: 2032

A Systematic Review of Treatment Strategies in VEXAS Syndrome

10:30AM-12:30PM: Abstract Number: 2025

Autonomic Nervous System Dysfunction Common Among Patients with Long COVID:Diagnosis and Treatment Implications

10:30AM-12:30PM: Abstract Number: 2037

Can Tofacitinib Be the Saviour in Treatment of Refractory IgG4-Related Disease : A Multicentre Experience from India

10:30AM-12:30PM: Abstract Number: 2039

Canakinumab Treatment in Patients with Familial Mediterranean Fever: A Tertiary Center Experience

10:30AM-12:30PM: Abstract Number: 2026

Cardiovascular Risk Measured by PREVENT Calculator and Disease Activity in Patients with Systemic Lupus Erythematosus

10:30AM-12:30PM: Abstract Number: 2036

CCN6 Gene Mutation Induces Mitochondrial Dysfunction: The Cause of Progressive Pseudo-rheumatoid Dysplasia

10:30AM-12:30PM: Abstract Number: 2050

Clinical Enthesitis Concerns Half the Patients with Psoriatic Arthritis, Is More Frequent in Trials Than in Observational Studies and Is Assessed Heterogeneously: A Systematic Review with Meta-analysis of 84,262 Patients from 212 Studies

10:30AM-12:30PM: Abstract Number: 2027

Clinical Features and Treatment of Retroperitoneal Fibrosis in a Referral Hospital and Literature Review

10:30AM-12:30PM: Abstract Number: 2057

Clinical Features of Autoimmune Uveitis and Associated Factors with Reactivation Subtype Presentation from a Peruvian Multidisciplinary Reference Center

10:30AM-12:30PM: Abstract Number: 2051

Clinical Outcomes and Predictors of Relapse in Patients with IgG4-Related Disease Treated with Rituximab: A Real-World Experience

10:30AM-12:30PM: Abstract Number: 2044

Clinical Practice Patterns, Rilonacept Appropriate Use for Recurrent Pericarditis

10:30AM-12:30PM: Abstract Number: 2055

Demographic and Ocular Characteristics of Scleritis Patients with Systemic Rheumatologic Disease in the IRIS® Registry (Intelligent Research in Sight)

10:30AM-12:30PM: Abstract Number: 2045

Descriptive Study on the Use of Serum Levels of Immunoglobulin G4, Immunoglobulin E and Eosinophil Count as Serum Biomarkers Across Four Clinical Phenotypes of IgG4-Related Disease

10:30AM-12:30PM: Abstract Number: 2056

Deucravacitinib Treatment Did Not Impact Immune Response to SARS-CoV-2 Vaccines and Infection in Patients with Plaque Psoriasis: Results from the Phase 3 POETYK Long-Term Extension Trial

10:30AM-12:30PM: Abstract Number: 2046

Duration of Disease and Long-term Outcomes in Patients with Difficult-to-treat Recurrent Pericarditis: A Chronic Condition Treated with NSAIDs, Colchicine, Corticosteroids, and Anti-IL-1 Agents

10:30AM-12:30PM: Abstract Number: 2040

Effective Management of Idiopathic Recurrent Pericarditis with Anakinra in Clinical Practice

10:30AM-12:30PM: Abstract Number: 2034

Effectiveness and Tolerability of Tocilizumab in Systemic Autoimmune Rheumatic Disease Associated Intertistial Lung Disease

10:30AM-12:30PM: Abstract Number: 2043

Evaluation of Medication Adherence of FMF Patients Transitioned from a Pediatric Clinic to an Adult Clinic: A Cross-sectional Study

10:30AM-12:30PM: Abstract Number: 2049

Genetically Proxied Glucose‑lowering Drug Target and Risk of Immune Mediated Inflammatory Disease: A Mendelian Randomization Study

10:30AM-12:30PM: Abstract Number: 2041

Global Prevalence and Clinical Outcomes of Cogan Syndrome

10:30AM-12:30PM: Abstract Number: 2029

Iron Deficiency in Familial Mediterranean Fever: A Study on 211 Adult Patients from the JIR Cohort

10:30AM-12:30PM: Abstract Number: 2038

Nationwide Analysis of Adult Hospitalizations with Rheumatologic Conditions and Spontaneous Coronary Artery Dissection

10:30AM-12:30PM: Abstract Number: 2035

Older Age and Higher Erythrocyte Sedimentation Rate Are Associated with Increased Disease Burden at Diagnosis in a Cohort of IgG4-Related Disease Patients

10:30AM-12:30PM: Abstract Number: 2042

Overview of Lung Manifestations in Sarcoidosis and Various Treatment Approaches at a University Center

10:30AM-12:30PM: Abstract Number: 2054

Phenotypical Differences in VEXAS Syndrome, Where Are We a Year Later? Results from a National Cohort Focused on Rheumatological Patients

10:30AM-12:30PM: Abstract Number: 2053

Presence of ANA to Development of Rheumatic Diseases

10:30AM-12:30PM: Abstract Number: 2048

Prognostic Value of Bronchoalveolar Lavage in CTD-related Interstitial Lung Disease: An Observational Study

10:30AM-12:30PM: Abstract Number: 2052

Role of Scleroderma/myositis-related Autoantibodies Detected by Immunoblot to the Diagnosis of Systemic Autoimmune Rheumatic Diseases in 410 Patients from a Single Referral Center

10:30AM-12:30PM: Abstract Number: 2047

Safety in Patients with Latent Tuberculosis Who Received Concomitant Anti-Tuberculosis Medications: Analysis of 11 Studies of Guselkumab in Psoriatic Disease

10:30AM-12:30PM: Abstract Number: 2033

Scleritis and the Rheumatologist. Does the Type of Scleritis Help to Distinguish an Infectious Cause from an Immune Cause? Among the Immune Causes, Does It Help Differentiate Between Systemic Causes and Those Limited to the Eye?

10:30AM-12:30PM: Abstract Number: 2030

The Development of the EULAR Score for the Definition of Disease Activity in Adult-onset Still’s Disease; The “DAVID” Project

10:30AM-12:30PM: Abstract Number: 2028

Therapeutic Insights in VEXAS Syndrome from a Multicenter Study in Spain: Moving Towards Amore Specific and Effective Treatment

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].